Propofol EC50 for Inducing Loss of Consciousness in General Combined Epidural Anesthesia

Propofol EC50 for Inducing Loss of Consciousness in Gastrectomy: Combined General and Epidural Anesthesia Versus General Anesthesia

The beneficial of perioperative usage of thoracic epidural anesthesia and analgesia in various thoracic and upper abdominal surgery are well studied. However, intraoperative data are lacking whether combined thoracic epidural and general anesthesia have effect on the median (50%) effective effect-concentration (EC50) of propofol for inducing loss of consciousness (LOC). We performed this study among patients undergoing open gastrectomy in gastric cancer patients.

Sixty patients undergoing open gastrectomy were randomly assigned to two groups with thoracic combined general anesthesia (TEA+GA) or general anesthesia (GA) alone. Target-controlled infusion (TCI) of propofol was used for anesthesia induction. The initial propofol concentration of target effect-site (Ceprop) was 3.5 ug/ml and was increased stepwise by 0.5ug/ml at each 4 min intervals by an un-down sequential method to reach LOC. The predicted Ceprop at the time of LOC, intravenous anesthetics, vasopressor requirement, emergency time from anesthesia and postoperative numeric rating scale (NRS) were recorded and analyzed between two groups.

Study Overview

• Status: Completed
• Conditions: Gastric Cancer
• Intervention / Treatment: Drug: 5-8ml 0.375% ropivacaine; Other: 5-8ml normal saline

Detailed Description

After received the approvement of ethics committee of the Cancer Hospital of the University of Chinese Academy of Sciences (approval number IRB- 2021-214). 60 adult gastric cancer patients between 18-75 yrs, ASA physical state I and II, undergoing open gastrectomy, were enrolled in this study. The exclusion criteria included: patients with contraindications to epidural puncture or catheter placement; chronic or acute (within 48 h) intake of psychotropic drugs, benzodiazepines, anticonvulsants, or opioids; alcoholism; hepatic, renal, neurological or other organ dysfunction; younger than 18 years or older than 75 years; with allergic to local anesthetic solutions or opioids; received neo-adjuvant chemotherapy; as well as patients who refuse to receive epidural puncture.

Patients were randomly assigned to either TEA+GA group of GA group. The requirement for the modified up-down method was used to confirm sample size (1).

Preoperative arrangements 3-lead electrocardiogram, pulse oximetry and continuously invasive artery blood pressure via left radial artery() were measured for basic monitoring. A central venous catheter was placed in the right internal jugular vein for fluid input and central venous pressure measurement and its position was confirmed by ultrasound. Bispectral Index (BIS) monitor (VT94306, Aspect VISTA, Covidien IIc, MA, USA) was measured for monitoring the depth of anesthetic.

Thoracic Epidural Anesthesia Epidural puncture was performed in the left lateral position through the interspace between the eighth to ninth thoracic vertebra (T8-T9). Epidural catheter was inserted by median approach using "loss-of-resistance"technique and was placed advanced 4 cm cephalad. A test dose of 3ml, 1%, lidocaine was injected through the catheter after the aspiration test for blood and cerebrospinal fluid shows negative results. Non sensory and motor anesthesia after 4 min of test dose injection indicate the absence of accidental subarachnoid placement of the catheter. In group TEA+GA, 5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction, by the second anesthesiologist, to obtain a bilateral segmentary sensory block to pinprick between T4 and T12 dermatomes. Continuous infusion of 4-6 ml 0.375% ropivacaine was applied using micro-infusion pump after induction(2). In group GA, same dose of normal saline was administered before induction and during surgery.

General Anesthesia General anesthesia was induced by propofol plasma target-controlled infusion (TCI) (). To explore the EC50 of propofol for inducing LOC in two groups. We started induction using a series of predicted effect-site concentrations of propofol (Ceprop) with an equal step wise of 0.5 ug/ml, according to the up-down method of Dixon(1). The initial Ceprop for the first patient of each group was 3.5 ug/ml based on previous studies (3) . Positive response to propofol was defined as LOC happened within 4 min after start of TCI under initial concentration. Otherwise the response was taken as negative and propofol concentration was increased 0.5 ug/ml more each 4 min until patient reach LOC (LOC was defined as loss of response to verbal commands). The initial TCI Ceprop was increased by 0.5 ug/ml for the next patients if the previous patient shows negative in the same group. The initial TCI Ceprop was decreased by 0.5 ug/ml for the next patient if the previous patient shows positive in the same group. All the patients were increased by 0.5 ug/ml stepwise at 4 min intervals until they showed LOC. An interval of 4 min was based on the pharmacokinetic and pharmacodynamic (PK-PD) character of propofol in order to obtain the steady-state effect-site concentrations (4; 5). An intravenous of 0.25 mg/Kg oxycodone and 0.6 mg/Kg rocuronium were given after LOC to facilitate tracheal intubation.

Maintenance of anesthesia Anesthesia was maintained with propofol, remifentanil and rocuronium during surgery. Ceprop was adjusted in stepwise of 0.5 ug/ml to keep the BIS between 45 to 55 in two groups. The lowest Ceprop was 2.0 ug/ml to avoid intraoperative awareness. Concentration for remifentanil was between 0.05 ug/Kg/min and 0.25 ug/Kg/ min during surgery depend on the blood pressure. The maintenance doses of rocuronium was 0.15mg/Kg as required to maintain surgical paralysis (6). Patients with hypertension were treated with 10 mg urapidil or 5 mg diltiazem i.v and hypotension was treated initially by speeding Ringger's solution, infusion voluven, then decrease concentration of remifentanil by 0.05 ug/Kg/min until reach the lower limit of 0.05 ug/Kg/min and finally given 5mg ephedrine i.v. 80 ug phenylephrine or 1mg metaraminol were then given if hypotension was remaining.

Postoperative management Anesthetics were stopped when the final surgical suture was done and then 2-4mg/Kg of sugammadex was applied according to the train-of-four (TOF) ratio. The duration between the time of discontinuation of anesthetics and the time of spontaneous opening of eyes was defined as anesthesia emergency time. All patients received postoperative patient-controlled epidural analgesia (PCEA) 0f 0.175% ropivacaine with 0.7ug/ml sufentanil. The PCEA continuous infusion dose was 3-4 ml with patient-controlled bolus dose of 4-5ml depend on the height and weight of patient.

Patients were transferred to PACU after extubation and stay at least 60 min there. In PACU, pain intensity using numerical analogue score of 0-10, postoperative nausea, vomiting and times of hypotension were evaluated and recorded at 30min, 60min and the time leave PACU.

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Zhejiang
    • Hangzhou, Zhejiang, China, 310000
      • Cancer Hospital of The University of Chinese Academy of Sciences

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Gastric cancer patients age between 18-75 yrs;

ASA physical state I and II

Undergoing open gastrectomy

Exclusion Criteria:

With contraindications to epidural puncture or catheter placement

Chronic or acute (within 48 h) intake of psychotropic drugs, benzodiazepines, anticonvulsants, or opioids; alcoholism

Hepatic, renal, neurological or other organ dysfunctiony

Younger than 18 years or older than 75 years

Allergic to local anesthetic solutions or opioids

Received neo-adjuvant chemotherapy

Refuse to receive epidural puncture

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Single Group Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Combined epidural with general anesthesia; Patients in this group received 5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction.Followed by a continuous infusion of 4-6 ml 0.375% ropivacaine was applied using micro-infusion pump after induction during surgery.	Drug: 5-8ml 0.375% ropivacaine; 5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction in experimental group. Followed by a continuous infusion of 4-6 ml/h using micro-infusion pump after induction during surgery.; Other Names: Experimental
Sham Comparator: General anesthesia; In this group, same dose of normal saline was administered before induction and during surgery.	Other: 5-8ml normal saline; 5-8ml of normal saline depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction. Followed by a continuous infusion of 4-6 ml/h using micro-infusion pump after induction during surgery.; Other Names: Sham control

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Propofol EC50 for Inducing Loss of Conciousness	Recording propofol EC50 for inducing loss of conciousness between general with epidural anesthesia group and general group with propofol effect-site target-controlled infusion (TCI) system	From anesthesia induction to patient loss of consciousness, an average of 5 minutes.
Predicted Effect-site Concentration of Propofol (Ceprop) at Certain Time Points	Recording the effect-site concentration of propofol (Ceprop) which showed on target-controlled infusion (TCI) system at loss of consciousness and discontinuation of anesthetics	From anesthesia induction to the patient loss of consciousness, an average of 5 minutes.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Anesthetics Consumption	Recording the total propofol and reminfentanil consumption during surgery	From anesthesia induction to the end of surgery, an average of 2.5 hours.
Postoperative Exhaust Time	Recording the first postoperative exhaust time by daily follow up	0-14 days postoperatively

Collaborators and Investigators

• Sponsor: Wang Jiangling
• Investigators: Principal Investigator: Jiangling Wang, M.D, Cancer Hospital of The University of Chinese Academy of Sciences

Study record dates

Study Major Dates

• Study Start (Actual): November 20, 2021
• Primary Completion (Actual): May 25, 2022
• Study Completion (Actual): May 25, 2022

Study Registration Dates

• First Submitted: October 11, 2021
• First Submitted That Met QC Criteria: November 5, 2021
• First Posted (Actual): November 18, 2021

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: November 23, 2024
• Last Verified: November 1, 2024

More Information

Terms related to this study

• Keywords: Gastric cancer; Gastrectomy; Epidural anesthesia; Propofol EC50
• Additional Relevant MeSH Terms: Neurologic Manifestations; Nervous System Diseases; Neoplasms by Site; Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases; Neurobehavioral Manifestations; Consciousness Disorders; Stomach Neoplasms; Unconsciousness; Physiological Effects of Drugs; Peripheral Nervous System Agents; Anesthetics, Local; Anesthetics; Central Nervous System Depressants; Sensory System Agents; Ropivacaine
• Other Study ID Numbers: IRB-2021-214

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No